Skip to main content
. 2019 Mar 27;21(4):413–427. doi: 10.1016/j.neo.2019.03.003

Figure 3.

Figure 3

LOXL2 promotes lymphangiogenic activity via activation of the Akt-Snail and Erk signaling pathways. (A, B) LOXL2 induces the phosphorylation of Akt and Erk. (A) The protein levels of p-Akt, p-Erk, Akt, Erk in hLECs treated with LOXL2 determined by Western blotting. (B) The protein levels of p-Akt, p-Erk, Akt, Erk in hLECs treated with tumor CM and indicated reagents determined by Western blotting. (C) Immunoblot analysis of p-Akt, p-Erk, Snail expression in the LOXL2, LY294002 (inhibitor of PI3K/Akt) or U0126 (inhibitor of Erk) treated hLECs. Cells were pretreated with LY294002 and U0126 for 30 min, and then stimulated with LOXL2 for 30 min. (D) The effect of LY294002 and U0126 on invasion of hLECs induced by LOXL2. (E) Quantified results showing the relative tube formation activity of the hLECs pretreated with LY294002 and U0126. (F) qRT-PCR and Immunoblot analysis of Snail expression in the LECs transfected with two specific siRNAs. (G) Representative and quantified data showing the relative tube formation activity of LECs transfected siCtrl and Snail-siRNAs. The data are the means ± SD of three independent experiments. *P < .05; **P < .01; ***P < .001. Scale bar = 200 μm.